Abbott Laboratories vs Samumed
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
Market cap history
● Abbott Laboratories● Samumed
Revenue by fiscal year
US$ billions, as reported in each year's annual results.
Side by side
| Measure | Abbott Laboratories ABT · #116 in the world | Samumed |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | — |
| Founded | 1888 | 2008 |
| Size | ||
| Market cap | $181.1 B | — |
| Revenue | $44.3 B | — |
| Net income | $6.5 B | — |
| Employees | 115,000 | — |
| Valuation | ||
| P/E ratio | 38.5× | — |
| Price to sales | 3.8× | — |
| Price to book | 3.5× | — |
| Free cash flow yield | 4.1% | — |
| Profitability | ||
| Gross margin | 56.4% | — |
| Operating margin | 18.2% | — |
| Net margin | 14.7% | — |
| Return on equity | 13.1% | — |
| Return on invested capital | 11.2% | — |
| Growth | ||
| Revenue growth | 5.7% | — |
| Revenue growth, 3 years a year | 0.5% | — |
| Earnings per share growth | -51.3% | — |
| Financial strength | ||
| Debt to equity | 0.3× | — |
| Cash | ||
| Free cash flow margin | 16.7% | — |
| Shareholder returns | ||
| Dividend yield | 2.3% | — |
| Shareholder yield | 2.8% | — |
| Strength scores | ||
| Piotroski F-score | 6 of 9 | — |
| Altman Z-score zone | safe | — |
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap — |
▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither
More about Abbott Laboratories
More about Samumed
Sources#
Every figure on this page comes from these, with the date shown next to it.